<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109283">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01937364</url>
  </required_header>
  <id_info>
    <org_study_id>EIRH-13-1134</org_study_id>
    <nct_id>NCT01937364</nct_id>
  </id_info>
  <brief_title>Preventing Alcohol Withdrawal With Oral Baclofen</brief_title>
  <acronym>BACLOFEN III</acronym>
  <official_title>Preventing Alcohol Withdrawal With Oral Baclofen: A Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essentia Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Essentia Health</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine if the medication baclofen can prevent the symptoms
      of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS.
      This medication is most often used for patients who have spasticity of their muscles due to
      a neuromuscular disease.  In several European studies, and in an earlier study at Essentia
      Health (NCT00597701), baclofen has been found to have a significant effect on the severity
      of symptoms of AWS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Alcohol withdrawal severity as measured on CIWA-AR (Clinical Institute for Withdrawal Assessment) scale</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total benzodiazepine dose required</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.</description>
    <arm_group_label>Baclofen</arm_group_label>
    <other_name>lioresal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (&gt;21) admitted to inpatients units of 1 of 3 Essentia Health hospitals

          -  Patient placed on AWS watch protocol by admitting physicians.

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Unable to take swallow oral medications (tube-fed patients are to be excluded)

          -  Admitted for AWS or with CIWA-Ar score &gt;8 at baseline

          -  No alcohol intake for â‰¥ 48 hours or AUDIT score &lt;12 at baseline

          -  Baclofen use at baseline

          -  Baclofen sensitivity

          -  Hospital discharge anticipated in within 48 hours

          -  Pregnant or breast feeding (urine pregnancy test required of women of child-bearing
             potential)

          -  Other active drug dependence (except tobacco)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey E Lyon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Essentia Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey E Lyon, MD</last_name>
    <phone>218-786-2802</phone>
    <email>jeffrey.lyon@essentiahealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven C Waring, DVM,PhD</last_name>
    <phone>218-786-1280</phone>
    <email>steven.waring@essentiahealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey E Lyon, MD</last_name>
      <phone>218-786-2802</phone>
      <email>jeffrey.lyon@essentiahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey E Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Innovis Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Neumann, MD</last_name>
      <email>james.neumann@essentiahealth.org</email>
    </contact>
    <investigator>
      <last_name>James Neumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Essentia Health</investigator_affiliation>
    <investigator_full_name>Jeffrey E Lyon</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
